Giovanna Beauchamp , Mary M. Barr , Ariana Vergara , Ambika Ashraf , Fernando Bril
{"title":"治疗与2型糖尿病儿童NAFLD改善无关的高血糖","authors":"Giovanna Beauchamp , Mary M. Barr , Ariana Vergara , Ambika Ashraf , Fernando Bril","doi":"10.1016/j.ijpam.2021.02.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and objectives</h3><p>Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) have become public health problems in the pediatric population. However, the relationship between these two conditions is not well understood. The primary objective of this study was to assess whether treatment of hyperglycemia in obese, treatment-naive children with type 2 diabetes (T2DM) was associated with an improvement of surrogate markers of NAFLD.</p></div><div><h3>Materials and methods</h3><p>This retrospective, longitudinal study included 151 obese children with a diagnosis of T2DM (Age: 14 ± 1 years, 72% female children, BMI: 98.6th percentile, and A1c: 10.3 ± 0.2%). Clinical/demographic information was collected before patients started any diabetes treatment and 1 and 3 years after starting metformin and/or insulin therapy.</p></div><div><h3>Results</h3><p>Forty-eight patients (32%) had abnormal ALT/AST (i.e., >40 U/L), suggestive of NAFLD. After 1 year of therapy, there were no significant differences in plasma ALT among patients started on insulin, metformin, or combination: 5±4 vs. −10 ± 3 vs. −2±2 IU/L, respectively, <em>P</em> = .07. Of note, changes in plasma ALT were small, despite a significant reduction of A1c in patients prescribed insulin (alone or with metformin): -2.8 ± 1.0%, <em>P</em> = .01, and −2.7 ± 0.3%, <em>P</em> < .001, respectively. In line with this, no significant correlations were found between changes in A1c and plasma aminotransferases. In contrast, changes in plasma AST/ALT were more strongly associated with BMI changes (r = 0.32, <em>P</em> < .001, and r = 0.19, <em>P</em> = .04, respectively). Similar results were observed after 3 years of follow-up.</p></div><div><h3>Conclusions</h3><p>Nonalcoholic fatty liver disease is highly prevalent in obese children with T2DM. Treatment of hyperglycemia with metformin and/or insulin did not result in any significant improvement in surrogate markers of NAFLD (i.e., plasma aminotransferases). While changes in ALT and/or AST may not perfectly reflect histological changes in NAFLD, our findings suggest that the treatment of hyperglycemia <em>per se</em> may not be associated with NAFLD improvement.</p></div>","PeriodicalId":36646,"journal":{"name":"International Journal of Pediatrics and Adolescent Medicine","volume":"9 2","pages":"Pages 83-88"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijpam.2021.02.007","citationCount":"4","resultStr":"{\"title\":\"Treatment of hyperglycemia not associated with NAFLD improvement in children with type 2 diabetes mellitus\",\"authors\":\"Giovanna Beauchamp , Mary M. Barr , Ariana Vergara , Ambika Ashraf , Fernando Bril\",\"doi\":\"10.1016/j.ijpam.2021.02.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and objectives</h3><p>Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) have become public health problems in the pediatric population. However, the relationship between these two conditions is not well understood. The primary objective of this study was to assess whether treatment of hyperglycemia in obese, treatment-naive children with type 2 diabetes (T2DM) was associated with an improvement of surrogate markers of NAFLD.</p></div><div><h3>Materials and methods</h3><p>This retrospective, longitudinal study included 151 obese children with a diagnosis of T2DM (Age: 14 ± 1 years, 72% female children, BMI: 98.6th percentile, and A1c: 10.3 ± 0.2%). Clinical/demographic information was collected before patients started any diabetes treatment and 1 and 3 years after starting metformin and/or insulin therapy.</p></div><div><h3>Results</h3><p>Forty-eight patients (32%) had abnormal ALT/AST (i.e., >40 U/L), suggestive of NAFLD. After 1 year of therapy, there were no significant differences in plasma ALT among patients started on insulin, metformin, or combination: 5±4 vs. −10 ± 3 vs. −2±2 IU/L, respectively, <em>P</em> = .07. Of note, changes in plasma ALT were small, despite a significant reduction of A1c in patients prescribed insulin (alone or with metformin): -2.8 ± 1.0%, <em>P</em> = .01, and −2.7 ± 0.3%, <em>P</em> < .001, respectively. In line with this, no significant correlations were found between changes in A1c and plasma aminotransferases. In contrast, changes in plasma AST/ALT were more strongly associated with BMI changes (r = 0.32, <em>P</em> < .001, and r = 0.19, <em>P</em> = .04, respectively). Similar results were observed after 3 years of follow-up.</p></div><div><h3>Conclusions</h3><p>Nonalcoholic fatty liver disease is highly prevalent in obese children with T2DM. Treatment of hyperglycemia with metformin and/or insulin did not result in any significant improvement in surrogate markers of NAFLD (i.e., plasma aminotransferases). While changes in ALT and/or AST may not perfectly reflect histological changes in NAFLD, our findings suggest that the treatment of hyperglycemia <em>per se</em> may not be associated with NAFLD improvement.</p></div>\",\"PeriodicalId\":36646,\"journal\":{\"name\":\"International Journal of Pediatrics and Adolescent Medicine\",\"volume\":\"9 2\",\"pages\":\"Pages 83-88\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ijpam.2021.02.007\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Pediatrics and Adolescent Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2352646721000247\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pediatrics and Adolescent Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352646721000247","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 4
摘要
背景与目的非酒精性脂肪性肝病(NAFLD)和2型糖尿病(T2DM)已成为儿童人群中的公共卫生问题。然而,这两种情况之间的关系还没有得到很好的理解。本研究的主要目的是评估肥胖、未接受治疗的2型糖尿病(T2DM)患儿的高血糖治疗是否与NAFLD替代标志物的改善相关。材料与方法回顾性、纵向研究纳入151例诊断为T2DM的肥胖儿童(年龄:14±1岁,72%为女童,BMI: 98.6%, A1c: 10.3±0.2%)。在患者开始任何糖尿病治疗前和开始二甲双胍和/或胰岛素治疗后1年和3年收集临床/人口统计信息。结果48例(32%)患者ALT/AST异常(≥40 U/L),提示NAFLD。治疗1年后,胰岛素、二甲双胍或联合用药的患者血浆ALT无显著差异:分别为5±4 IU/L vs - 10±3 IU/L vs - 2±2 IU/L, P = 0.07。值得注意的是,血浆ALT的变化很小,尽管使用胰岛素(单独使用或联合使用二甲双胍)的患者的A1c显著降低:-2.8±1.0%,P = 0.01,和- 2.7±0.3%,P <分别措施。与此相一致的是,在A1c和血浆转氨酶的变化之间没有发现显著的相关性。相比之下,血浆AST/ALT的变化与BMI变化的相关性更强(r = 0.32, P <.001, r = 0.19, P = 0.04)。在3年的随访后观察到类似的结果。结论非酒精性脂肪肝在肥胖儿童合并2型糖尿病中高发。用二甲双胍和/或胰岛素治疗高血糖没有导致NAFLD替代标志物(即血浆转氨酶)的任何显著改善。虽然ALT和/或AST的变化可能不能完全反映NAFLD的组织学变化,但我们的研究结果表明,治疗高血糖本身可能与NAFLD的改善无关。
Treatment of hyperglycemia not associated with NAFLD improvement in children with type 2 diabetes mellitus
Background and objectives
Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) have become public health problems in the pediatric population. However, the relationship between these two conditions is not well understood. The primary objective of this study was to assess whether treatment of hyperglycemia in obese, treatment-naive children with type 2 diabetes (T2DM) was associated with an improvement of surrogate markers of NAFLD.
Materials and methods
This retrospective, longitudinal study included 151 obese children with a diagnosis of T2DM (Age: 14 ± 1 years, 72% female children, BMI: 98.6th percentile, and A1c: 10.3 ± 0.2%). Clinical/demographic information was collected before patients started any diabetes treatment and 1 and 3 years after starting metformin and/or insulin therapy.
Results
Forty-eight patients (32%) had abnormal ALT/AST (i.e., >40 U/L), suggestive of NAFLD. After 1 year of therapy, there were no significant differences in plasma ALT among patients started on insulin, metformin, or combination: 5±4 vs. −10 ± 3 vs. −2±2 IU/L, respectively, P = .07. Of note, changes in plasma ALT were small, despite a significant reduction of A1c in patients prescribed insulin (alone or with metformin): -2.8 ± 1.0%, P = .01, and −2.7 ± 0.3%, P < .001, respectively. In line with this, no significant correlations were found between changes in A1c and plasma aminotransferases. In contrast, changes in plasma AST/ALT were more strongly associated with BMI changes (r = 0.32, P < .001, and r = 0.19, P = .04, respectively). Similar results were observed after 3 years of follow-up.
Conclusions
Nonalcoholic fatty liver disease is highly prevalent in obese children with T2DM. Treatment of hyperglycemia with metformin and/or insulin did not result in any significant improvement in surrogate markers of NAFLD (i.e., plasma aminotransferases). While changes in ALT and/or AST may not perfectly reflect histological changes in NAFLD, our findings suggest that the treatment of hyperglycemia per se may not be associated with NAFLD improvement.